Skip to main content
Top
Published in: Supportive Care in Cancer 12/2013

01-12-2013 | Original Article

Correlation of radiation treatment interruptions with psychiatric disease and performance status in head and neck cancer patients

Authors: Radhika Sreeraman, Srinivasan Vijayakumar, Allen M. Chen

Published in: Supportive Care in Cancer | Issue 12/2013

Login to get access

Abstract

Purpose

The purpose of this study is to identify factors predictive of treatment interruptions during radiation therapy (RT) for head and neck cancer.

Methods and materials

The medical records of 280 consecutive patients who completed a 6- or 7-week course of RT for squamous cell carcinoma of the head and neck were reviewed. The number of missed treatment days, excluding those due to holidays or machine downtime, was determined for each patient. All patients were treated to a median dose of 63 Gy (range, 60 to 70 Gy).

Results

The proportion of patients who missed 0, 3–5, 6–10, and greater than 10 days was 25, 59, 12, and 5 %, respectively. The percentage of patients who missed greater than 5 days was 62 % among the 39 patients with Karnofsky Performance Status (KPS) score of 70 or less compared to 10 % among those with a KPS score of greater than 70 (p < 0.01). Among the 33 patients identified with a preexisting psychiatric condition, the percentage that subsequently missed greater than 5 days of treatment was 48 % compared to 13 % among those without a psychiatric condition. When missed RT days were analyzed as a continuous variable, the correlations with both KPS and preexisting psychiatric condition remained highly significant (p < 0.01, for both).

Conclusion

Poor performance status and preexisting psychiatric condition predicted for treatment interruptions during RT for head and neck cancer. In view of the possible detrimental effect on treatment outcome, appropriate social programs should be initiated to overcome potential barriers to RT for these particular populations.
Literature
1.
go back to reference Robertson AG, Robertson C, Perone C et al (1998) Effect of gap length and position on results of treatment of cancer of the larynx in Scotland by radiotherapy: a linear quadratic analysis. Radiother Oncol 48:165–173PubMedCrossRef Robertson AG, Robertson C, Perone C et al (1998) Effect of gap length and position on results of treatment of cancer of the larynx in Scotland by radiotherapy: a linear quadratic analysis. Radiother Oncol 48:165–173PubMedCrossRef
2.
go back to reference Groome PA, O’Sullivan B, Mackillop WJ et al (2006) Compromised local control due to treatment interruptions and late treatment breaks in early glottic cancer: population-based outcomes study supporting need for intensified treatment schedules. Int J Radiat Oncol Biol Phys 64:1002–1012PubMedCrossRef Groome PA, O’Sullivan B, Mackillop WJ et al (2006) Compromised local control due to treatment interruptions and late treatment breaks in early glottic cancer: population-based outcomes study supporting need for intensified treatment schedules. Int J Radiat Oncol Biol Phys 64:1002–1012PubMedCrossRef
3.
go back to reference Suwinski R, Sowa A, Rutkowski T et al (2003) Time factor in postoperative radiotherapy: a multivariate locoregional control analysis in 868 patients. Int J Radiat Oncol Biol Phys 56:399–412PubMedCrossRef Suwinski R, Sowa A, Rutkowski T et al (2003) Time factor in postoperative radiotherapy: a multivariate locoregional control analysis in 868 patients. Int J Radiat Oncol Biol Phys 56:399–412PubMedCrossRef
4.
go back to reference Robertson C, Robertson AG, Hendry JH et al (1998) Similar decreases in local tumor control are calculated for treatment protraction and for interruptions in the radiotherapy of carcinoma of the larynx in four centers. Int J Radiat Oncol Biol Phys 40:319–329PubMedCrossRef Robertson C, Robertson AG, Hendry JH et al (1998) Similar decreases in local tumor control are calculated for treatment protraction and for interruptions in the radiotherapy of carcinoma of the larynx in four centers. Int J Radiat Oncol Biol Phys 40:319–329PubMedCrossRef
5.
go back to reference Fesinmeyer MD, Mehta V, Blough D et al (2010) Effect of radiotherapy interruptions on survival in medicare enrollees with local and regional head-and-neck cancer. Int J Radiat Oncol Biol Phys 78:675–681PubMedCrossRef Fesinmeyer MD, Mehta V, Blough D et al (2010) Effect of radiotherapy interruptions on survival in medicare enrollees with local and regional head-and-neck cancer. Int J Radiat Oncol Biol Phys 78:675–681PubMedCrossRef
6.
go back to reference Badiee J, Riggs PK, Rooney AS et al (2012) Approaches to identifying appropriate medication adherence assessments for HIV infected individuals with comorbid bipolar disorder. AIDS Patient Care STDS 26:388–394PubMed Badiee J, Riggs PK, Rooney AS et al (2012) Approaches to identifying appropriate medication adherence assessments for HIV infected individuals with comorbid bipolar disorder. AIDS Patient Care STDS 26:388–394PubMed
7.
go back to reference Gentil L, Vasiliadis HM, Preville M et al (2012) Association between depressive and anxiety disorders and adherence to antihypertensive medication in community-living elderly adults. J Am Geriatr Soc 60:2297–2301PubMedCrossRef Gentil L, Vasiliadis HM, Preville M et al (2012) Association between depressive and anxiety disorders and adherence to antihypertensive medication in community-living elderly adults. J Am Geriatr Soc 60:2297–2301PubMedCrossRef
8.
go back to reference Therneau TM, Atkinson EJ (1997) An introduction to recursive partitioning using the RPART routines. Mayo Foundation, Rochester, MN, pp 13–14 Therneau TM, Atkinson EJ (1997) An introduction to recursive partitioning using the RPART routines. Mayo Foundation, Rochester, MN, pp 13–14
9.
go back to reference Withers HR, Taylor JMG, Maciejewski B (1988) The hazard of accelerated tumour clonogen repopulation during radiotherapy. Acta Oncol 27:131–146PubMedCrossRef Withers HR, Taylor JMG, Maciejewski B (1988) The hazard of accelerated tumour clonogen repopulation during radiotherapy. Acta Oncol 27:131–146PubMedCrossRef
10.
go back to reference Hendry JH (1992) Treatment acceleration in radiotherapy: the relative time factors and dose–response slopes for tumors and normal tissues. Radiother Oncol 25:308–312PubMedCrossRef Hendry JH (1992) Treatment acceleration in radiotherapy: the relative time factors and dose–response slopes for tumors and normal tissues. Radiother Oncol 25:308–312PubMedCrossRef
11.
go back to reference Peters LJ, Withers HR (1997) Applying radiobiological principles to combined modality treatment of head and neck cancer—the time factor. Int J Radiat Oncol Biol Phys 39:831–836PubMedCrossRef Peters LJ, Withers HR (1997) Applying radiobiological principles to combined modality treatment of head and neck cancer—the time factor. Int J Radiat Oncol Biol Phys 39:831–836PubMedCrossRef
12.
go back to reference Pajak TF, Laramore GE, Marcial VA et al (1991) Elapsed treatment days—a critical item for radiotherapy quality control review in head and neck trials: RTOG report. Int J Radiat Oncol Biol Phys 20(1):13–20PubMedCrossRef Pajak TF, Laramore GE, Marcial VA et al (1991) Elapsed treatment days—a critical item for radiotherapy quality control review in head and neck trials: RTOG report. Int J Radiat Oncol Biol Phys 20(1):13–20PubMedCrossRef
13.
go back to reference Fu KK, Pajak TF, Trotti A et al (2000) A Radiation Therapy Oncology Group (RTOG) phase III randomized study to compare hyperfractionation and two variants of accelerated fractionation to standard fractionation radiotherapy for head and neck squamous cell carcinomas: first report of RTOG 9003. Int J Radiat Oncol Biol Phys 48:7–16PubMedCrossRef Fu KK, Pajak TF, Trotti A et al (2000) A Radiation Therapy Oncology Group (RTOG) phase III randomized study to compare hyperfractionation and two variants of accelerated fractionation to standard fractionation radiotherapy for head and neck squamous cell carcinomas: first report of RTOG 9003. Int J Radiat Oncol Biol Phys 48:7–16PubMedCrossRef
14.
go back to reference Siddoqio F, Pajak TF, Watkins-Bruner D et al (2008) Pretreatment quality of life predicts for locoregional control in head and neck cancer patients: a radiation therapy oncology group analysis. Int J Radiat Oncol Biol Phys 70:353–360CrossRef Siddoqio F, Pajak TF, Watkins-Bruner D et al (2008) Pretreatment quality of life predicts for locoregional control in head and neck cancer patients: a radiation therapy oncology group analysis. Int J Radiat Oncol Biol Phys 70:353–360CrossRef
15.
go back to reference Karvonen-Gutierrez CA, Ronis DL, Fowler KE et al (2008) Quality of life scores predict survival among patients with head and neck cancer. J Clin Oncol 26:2754–2760PubMedCrossRef Karvonen-Gutierrez CA, Ronis DL, Fowler KE et al (2008) Quality of life scores predict survival among patients with head and neck cancer. J Clin Oncol 26:2754–2760PubMedCrossRef
16.
go back to reference Jeremic B, Milicic B (2009) Pretreatment prognostic factors of survival in patients with locally advanced nonmetastatic squamous cell carcinoma of the head and neck treated with radiation therapy with or without concurrent chemotherapy. Am J Clin Oncol 32:163–168PubMedCrossRef Jeremic B, Milicic B (2009) Pretreatment prognostic factors of survival in patients with locally advanced nonmetastatic squamous cell carcinoma of the head and neck treated with radiation therapy with or without concurrent chemotherapy. Am J Clin Oncol 32:163–168PubMedCrossRef
17.
go back to reference De Leeuw JR, De Graeff A, Ros WJ et al (2000) Negative and positive influences of social support on depression in patients with head and neck cancer: a prospective study. Psychooncology 9:20–28PubMedCrossRef De Leeuw JR, De Graeff A, Ros WJ et al (2000) Negative and positive influences of social support on depression in patients with head and neck cancer: a prospective study. Psychooncology 9:20–28PubMedCrossRef
18.
go back to reference Lazure KE, Lydiatt WM, Denman D et al (2008) Association between depression and survival or disease recurrence in patients with head and neck cancer enrolled in a depression prevention trial. Head Neck 31:888–892CrossRef Lazure KE, Lydiatt WM, Denman D et al (2008) Association between depression and survival or disease recurrence in patients with head and neck cancer enrolled in a depression prevention trial. Head Neck 31:888–892CrossRef
19.
go back to reference Westin T, Jansson Z, Zenckert C et al (1988) Mental depression is associated with malnutrition in patients with head and neck cancer. Arch Otolaryngol head Neck Surg 14:1449–1453CrossRef Westin T, Jansson Z, Zenckert C et al (1988) Mental depression is associated with malnutrition in patients with head and neck cancer. Arch Otolaryngol head Neck Surg 14:1449–1453CrossRef
20.
go back to reference Konski AA, Pajak TF, Movsas B et al (2006) Disadvantage of men living alone participating in Radiation Therapy Oncology Group head and neck trials. J Clin Oncol 24:4177–4183PubMedCrossRef Konski AA, Pajak TF, Movsas B et al (2006) Disadvantage of men living alone participating in Radiation Therapy Oncology Group head and neck trials. J Clin Oncol 24:4177–4183PubMedCrossRef
21.
go back to reference Kugaya A, Akechi T, Okuyama T et al (2000) Prevalence, predictive factors, and screening for psychologic distress in patients with newly diagnosed head and neck cancer. Cancer 88:2817–2823PubMedCrossRef Kugaya A, Akechi T, Okuyama T et al (2000) Prevalence, predictive factors, and screening for psychologic distress in patients with newly diagnosed head and neck cancer. Cancer 88:2817–2823PubMedCrossRef
22.
go back to reference Katz MR, Kopek N, Waldron J et al (2004) Screening for depression in head and neck cancer. Psychooncology 13:269–280PubMedCrossRef Katz MR, Kopek N, Waldron J et al (2004) Screening for depression in head and neck cancer. Psychooncology 13:269–280PubMedCrossRef
23.
go back to reference McCaffrey JC, Weitzner M, Kamboukas D et al (2007) Alcoholism, depression, and abnormal cognition in head and neck cancer: a pilot study. Otolaryngol Head Neck Surg 136:92–97PubMedCrossRef McCaffrey JC, Weitzner M, Kamboukas D et al (2007) Alcoholism, depression, and abnormal cognition in head and neck cancer: a pilot study. Otolaryngol Head Neck Surg 136:92–97PubMedCrossRef
24.
go back to reference DiMatteo MR, Lepper HS, Croghan TW (2000) Depression is a risk factor for noncompliance with medical treatment: meta-analysis of the effects of anxiety and depression on patient adherence. Arch Intern Med 160:2101–2107PubMedCrossRef DiMatteo MR, Lepper HS, Croghan TW (2000) Depression is a risk factor for noncompliance with medical treatment: meta-analysis of the effects of anxiety and depression on patient adherence. Arch Intern Med 160:2101–2107PubMedCrossRef
25.
go back to reference Jenkins C, Carmody TJ, Rush AJ (1998) Depression in radiation oncology patients: a preliminary evaluation. J Affect Disord 50:17–21PubMedCrossRef Jenkins C, Carmody TJ, Rush AJ (1998) Depression in radiation oncology patients: a preliminary evaluation. J Affect Disord 50:17–21PubMedCrossRef
26.
go back to reference Roscoe JA, Kaufman ME, Matteson-Rusby SE et al (2007) Cancer-related fatigue and sleep disorders. Oncologist 12:35–42PubMedCrossRef Roscoe JA, Kaufman ME, Matteson-Rusby SE et al (2007) Cancer-related fatigue and sleep disorders. Oncologist 12:35–42PubMedCrossRef
27.
go back to reference Pasik SD, Dugan W, McDonald MV et al (1998) Oncologists’ recognition of depression in their patients with cancer. J Clin Oncol 16:1594–1600 Pasik SD, Dugan W, McDonald MV et al (1998) Oncologists’ recognition of depression in their patients with cancer. J Clin Oncol 16:1594–1600
28.
go back to reference Patel U, Thakkar K, Holloway N (2008) Patient compliance to radiation for advanced head and neck cancer at a tertiary care county hospital. Laryngoscope 118:428–432PubMedCrossRef Patel U, Thakkar K, Holloway N (2008) Patient compliance to radiation for advanced head and neck cancer at a tertiary care county hospital. Laryngoscope 118:428–432PubMedCrossRef
29.
go back to reference Bese NS, Hendry J, Jeremic B (2007) Effects of prolongation of overall treatment time due to unplanned interruptions during radiotherapy of different tumor sites and practical methods for compensation. Int J Radiat Oncol Biol Phys 68:654–661PubMedCrossRef Bese NS, Hendry J, Jeremic B (2007) Effects of prolongation of overall treatment time due to unplanned interruptions during radiotherapy of different tumor sites and practical methods for compensation. Int J Radiat Oncol Biol Phys 68:654–661PubMedCrossRef
30.
go back to reference James ND, Williams MV, Summers ET et al (2008) The management of interruptions to radiotherapy in head and neck cancer: an audit of the effectiveness of national guidelines. Clin Oncol 20:599–605CrossRef James ND, Williams MV, Summers ET et al (2008) The management of interruptions to radiotherapy in head and neck cancer: an audit of the effectiveness of national guidelines. Clin Oncol 20:599–605CrossRef
31.
go back to reference Macia I, Garau M, Sole Monne J et al (2009) Compliance to the prescribed overall treatment time (OTT) of curative radiotherapy in normal clinical practice and impact on treatment duration of counteracting short interruptions by treating patients on Saturdays. Clin Transl Oncol 11:302–311CrossRef Macia I, Garau M, Sole Monne J et al (2009) Compliance to the prescribed overall treatment time (OTT) of curative radiotherapy in normal clinical practice and impact on treatment duration of counteracting short interruptions by treating patients on Saturdays. Clin Transl Oncol 11:302–311CrossRef
Metadata
Title
Correlation of radiation treatment interruptions with psychiatric disease and performance status in head and neck cancer patients
Authors
Radhika Sreeraman
Srinivasan Vijayakumar
Allen M. Chen
Publication date
01-12-2013
Publisher
Springer Berlin Heidelberg
Published in
Supportive Care in Cancer / Issue 12/2013
Print ISSN: 0941-4355
Electronic ISSN: 1433-7339
DOI
https://doi.org/10.1007/s00520-013-1907-3

Other articles of this Issue 12/2013

Supportive Care in Cancer 12/2013 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine